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Neuregulin 1 (NRG1), a ligand for human epidermal growth factor (HER) 3 
and HER4, can activates cell signaling pathways to promote carcinogenesis 
and metastasis. To investigate the clinicopathologic significance of NRG1 and 
its receptors, immunohistochemistry was performed for NRG1, HER3, and 
HER4 in 502 consecutive gastric cancers (GCs). Furthermore, HER2, 
microsatellite instability (MSI), and Epstein-Barr virus (EBV) status were 
investigated. NRG1 gene copy number (GCN) was determined by dual-color 
fluorescence in situ hybridization (FISH) in 388 available GCs. NRG1 
overexpression was observed in 141 (28.1%) GCs and significantly associated 
with aggressive features, including infiltrative tumor growth, lymphovascular, 
and neural invasion, high pathologic stage, and poor prognosis (all P < 0.05), 
but not associated with EBV, MSI, or HER2 status. HER3 cytoplasmic and 
membranous expression were observed in 157 (31.3%) and 13 (2.6%), 
respectively. HER4 cytoplasmic expression was observed in 277 (55.2%), 
including 115 (22.9%) cases with nuclear expression. In contrast to NRG1, 
cytoplasmic expression of HER3 and HER4 proteins were not associated with 
survival, but GC patients with HER3 membranous expression showed 
significantly worse survival. In addition, HER4 nuclear expression was 
inveresely correlated with patients outcome in GC. NRG1 overexpression was 
also closely correlated with HER3 (P = 0.034) and HER4 (P < 0.001) 
cytoplasmic expression. NRG1 GCN gain (GCN ≥ 2.5) was detected in 14.7% 
patients, including two cases of amplification, and was moderately correlated 
with NRG1 overexpression (κ, 0.459; P < 0.001). Multivariate analysis 
identified NRG1 overexpression as an independent prognostic factor for 
survival (P = 0.040), unlike HER3 and HER4 expression. In 14 HER2 
positive GC with trastzumab combined chemotherapy, coexpression of NRG1 
and HER3 was detected in 2 (14.3%) cases, and these GC patients group with  
coexpression of NRG1 and HER3 also showed a shorter PFS (P = 0.005). 
Although our results indicate a lack of prognostic significance of HER3 and 
HER4 overexpression in GC, overexpression of their ligand, NRG1, was 
associated with aggressive clinical features and represented an independent 
unfavorable prognostic factor. Therefore, NRG1 is a potential prognostic and 




Keywords     : Gastric cancer, Neuregulin1, Immunohistochemistry, 
Fluorescence in situ hybridization, Copy number gain 
Student Number: 2014-30678 





List of tables……………………….………………………………….…….  v 
 














Abstract in Korean………………………………………………………... 61 
LIST OF TABLES 
Table 1. Clinicopathological characteristics of patients..….…….…..............15 
Table 2. The correlation between clinicopathologic parameters and expression 
status of NRG1, HER3, and HER4....................................................17 
Table 3. Univariate and multivariate analysis for disease free survival and 
       disease specific survival in gastric cancer………………………….26 
Table 4. Correlation between NRG1 IHC and GCN status………………….29 
Table 5. Clinicopathological implications of NRG1 GCN gain…………......30 
Table 6. Clinicopathological implications of HER3 membranous and HER4 
nuclear expression………………………………….....…………… 33 
Table 7. Correlation between expression of NRG1, HER3, and HER4……..40 
Table 8. Clinicopathologic characteristics of HER2 positive and trastzumab 
treated GC cases and immunohistochemical staining of NRG1 and 
HER3.................................................................................................42 
LIST OF FIGURES 
Figure 1. Representative images of NRG1, HER3, and HER4 protein 
expression in non-neoplastic gastric mucosa…………..…………….7 
Figure 2. Representative images of NRG1, HER3, and HER4 protein 
expression in GC specimens..…....……………………………....… .8 
Figure 3. Representative images of the NRG1 FISH assay in GC …………..11 
Figure 4. Kaplan-Meier survival estimates according to NRG1, HER3 and 
HER4 protein expression, and NRG1 GCN status………………… 22 
Figure 5. Kaplan-Meier survival estimates according to NRG1, HER3 and 
HER4 protein expression (excluding cases with 1 months of follow 
up)..................................................................................................... 24 
Figure 6. Survival curves according to HER3 membranous and HER4 nuclear 
expression………………………………………………………..... 36 
Figure 7. Survival curves according to HER3 membranous and HER4 nuclear  
expression (excluding cases with ≤1 months of follow up)……….. 37
Figure 8. NRG1 and HER3 expression in HER2 positive and trastzumab 
treated GC …………………………………….…..………………..43 
Figure 9. Kaplan-Meier survival analysis accoridng to NRG1 and HER3  
expression in HER2 positive and trastzumab treated GC patients....44 
INTRODUCTION 
 
Despite recent diagnostic and therapeutic advances, gastric cancer (GC) 
remains a leading cause of cancer deaths, particularly in South Korea [1]. 
Deeper understanding of the molecular pathogenesis of GC has contributed to 
successful clinical application of targeted drugs, for example, drugs targeting 
to human epidermal growth factor receptor (HER) 2 mutations [2]. The HER 
family consists of four transmembrane proteins, HER1 (EGFR), HER2, HER3, 
and HER4. HER2 is well studied and can induce cell proliferation, 
differentiation, and apoptosis [2]. HER2 overexpression has been found in a 
subset (20–30%) of GC samples, primarily as a result of HER2 gene 
amplification [2,3], and currently, drugs targeting HER2-positive GC are 
increasingly used as part of treatment for patients with advanced GC, as they 
can significantly improve outcomes [3, 4]. Unfortunately, a significant 
number of these patients eventually develop drug resistance and exhibit poor 
survival rates [4, 5]; hence, recent studies have focused on other members of 
the HER family, including HER3 and HER4 and their ligands. 
 
Neuregulin (NRG) is a ligand of HER family protein, which has more than 32 
isoforms. NRG1 is the predominant ligand of HER3 and HER4. Through 
binding to HER3, it functions in specific regulation of cell proliferation and 
organ development [6, 7]. Additionally, NRG1 can induce carcinoma 
development and promote metastasis [7]. Interestingly, recent studies have 
suggested that PI3K/Akt activation through the NRG1/HER3 signaling 
pathway leads to development of resistance to HER2-targeted treatment, and 
it has been proposed that inhibition of this signaling pathway has potential as 
a therapeutic option to overcome resistance to anti-HER2 treatment [8–11]. 
However, few studies have assessed the association of NRG1 status and GC 
or the clinicopathologic significance of the NRG1/HER3/HER2 and 
NRG1/HER4/HER2 axis in GC. 
 
Unlike other HER family proteins, HER3 lacks significant tyrosine kinase 
activity; it has a regulatory function through heterodimer formation with other 
members of the HER family [12]. Heterodimer containing HER3 can activate 
the following two key signaling pathways: mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase (PI3K)/Akt [12]. In various cancers, 
HER3/HER2/PI3K/Akt signaling promotes tumor cell proliferation and 
survival [6, 12, 13]. Several studies have demonstrated associations between 
HER3 protein expression and poor survival in various cancers including GC 
[14–17]. 
 
HER4 has markedly different functions in tumors, including functionally 
distinct splice isoforms and multiple proteolytically derived types. Alternative 
splicing of HER4 releases its intracellular domain and enables it to translocate 
to the nucleus [18–20]. Although the function of nuclear HER4 has not been 
fully elucidated, it has a role as a transcriptional cofactor [19]. Several 
previous studies have reported various prognostic associations with HER4 
immunohistochemistry (IHC) results, particularly in breast cancer, including a 
correlation between cytoplasmic HER4 and improved prognosis [18]. 
However, the prognostic role of cytoplasmic and nuclear expression of HER4 
in GC remains unclear. Moreover, detailed information regarding the 
mechanism of action of HER4 and its relationship with its ligand in GC is 
lacking [17]. 
 
In this study, we aimed to determine the prevalence and clinicopathologic 
implications of NRG1 expression in a large cohort of GC samples and to 
assess the relationship between NRG1 expression and that of HER3 and 
HER4. In addition, NRG1 expression status in GC was compared with HER2 
positivity, Epstein-Barr virus (EBV) in situ hybridization (ISH), and 
microsatellite instability (MSI) status. We evaluated the NRG1 gene copy 
number (GCN) status using dual-color fluorescence in situ hybridization 
(FISH) analysis and compared the concordance rate between protein 
expression and genetic alteration for NRG1.  
MATERIALS AND METHODS 
Patients and clinicopathological characteristics  
A total of 502 consecutive GC patients who had curative surgery at Seoul 
National University Bundang Hospital from May 2003 to December 2005 
were analyzed in this study. Clinical information including age, sex, size, 
location, and pathologic stage were collected from medical records 
retrospectively. Patients who had received preoperative chemotherapy or 
radiotherapy were excluded from this study. The American Joint Committee 
on Cancer seventh staging system was used to determine pTNM stage [21]. 
Disease-specific survival (DSS) data were collected, including patient 
outcome, the interval between the date of surgery and the date of death due to 
GC, and the period of disease-free survival (DFS) from surgery until the date 
of disease progression, death, or last disease assessment. In addition, to 
evaluate the prognostic impact of NRG1/HER3 signaling for HER2 targeting 
treatment, we collected 14 HER2 positive GC patients who had surgical 
operation and received chemotherapy combined with trastzumab at Seoul 
National University Bundang Hospital from 2009 to 2012.  
 
Tissue microarray (TMA) construction 
TMA blocks were constructed for 502 cases of GC, using previously 
described methods [22]. Briefly, we selected a representative tumor area for 
TMA construction in each case, and tissue cores of 2 mm diameter were 
transferred to the TMA block. Samples were considered valid when the tumor 
occupied more than 15% of the core area. Serial sections were cut and used 
for IHC and FISH analyses. 
 
Immunohistochemistry  
We performed IHC using anti-NRG1 (1:2000, Abcam, Cambridge, MA, USA), 
anti-HER3 (1:3000, Thermo Scientific, Fremont, CA, USA), anti-HER4 
(1:8000, Thermo scientific), and anti-HER2 (4B5; pre-dilution; Ventana,
Medical Systems, Tucson, AZ, USA) antibodies with a Ventana Benchmark 
automatic immunostaining system (BenchMark XT, Ventana Medical system), 
according to the manufacturer’s instructions. Antigen retrieval for 
immunohistochemistry consisted of Cell Conditioning 1 (CC1) (pH 8.4) for 
24 min at 100 . Sections on microslides were incubated with these 
antibodies and immunoreactivity detected using diaminobenzidine (DAB) 
substrate. Immunostaining was interpreted without prior knowledge of 
clinicopathologic data. NRG1, HER3, and HER4 were faintly expressed in the 
foveolar glands of non-neoplastic gastric mucosa; however, weak to moderate 
expression was observed in the cytoplasm of deep gastric glands (Fig. 1). In 
tumor cells, NRG1 expression was detected in the cytoplasm and HER3 
expression in the cytoplasm and/or membrane of tumor cells. HER4 
expression was also observed in the cytoplasm of tumor cells; however, a 
significant fraction of GC exhibited nuclear expression of HER4 (Fig. 2); 
Therefore, we recorded cytoplasmic and nuclear expression of HER4 
separately. We evaluated both the extent (%) and the intensity of positive 
tumor cells. The intensity of NRG1, HER3, and HER4 protein expression was 
classified into the following four categories according to the scoring system 
presented in a previous report [15]: 0, negative; 1+, weak positive; 2+, 
moderate positive; 3+, strong positive. For statistical analysis, cases with the 
immunostaining intensity of 2+ or 3+ in 10% or more tumor cells were 
defined as positive or overexpression of NRG1 and its receptors. 
 
Figure 1. Representative images of NRG1, HER3, and HER4 protein 
expression in non-neoplastic gastric mucosa. a NRG1 in foveolar epithelium. 
b NRG1 in deep gland. c HER3 in foveolar epithelium. d HER3 in deep gland. 
e HER4 in foveolar epithelium. f HER4 in deep gland. 
 
 
Figure 2. Representative images of NRG1, HER3, and HER4 protein 
expression in GC specimens. a NRG1 negative. b NRG1 positive. c HER3 
negative. d HER3 cytoplasmic positive. e HER4 negative. f HER4 
cytoplasmic positive. g HER3 membranous positive. h HER4 nuclear positive. 
NRG1 analysis by dual-color fluorescence in situ 
hybridization  
We performed FISH analysis to evaluate NRG1 GCN. Of the 502 cases, 388 
were interpretable by FISH analysis. Samples that were negative for tumor 
cells or without FISH signals were excluded. NRG1 gene status was evaluated 
by dual-color FISH assay according to the manufacturer’s instructions [23]. 
TMA slides (2 mm in thickness) were incubated with a NRG1 probe 
(Macrogen Inc., Seoul, Korea) and centromeric enumeration probe 8 (CEP8, 
Macrogen Inc., Seoul, Korea) with pepsin at 37  for 30 min. After being 
placed in HYBrite solution (Abbott Laboratories, Abbott Park, IL, USA) at 
74 , slides were counterstained with DAPI (Macrogen, Inc., Seoul, Korea). 
FISH analysis was evaluated without prior knowledge of clinicopathologic 
information. Entire cores were scanned and signals in 20 non-overlapping 
tumor nuclei counted in each core. If clusters were observed, small and large 
clusters were considered as 6 and 12 signals, respectively. NRG1 
amplification was defined as anNRG1/CEP8 ratio of ≥ 2.0. In addition to 
NRG1 amplification, increased NRG1 GCN signals were also observed. Since 
there are no standardized guidelines for evaluation of NRG1 gene status, we 
used a cutoff value adapted from a previous study on EGFR in GC [24]; hence, 
NRG1 GCN gain was defined as the copy number of NRG1 per nucleus of ≥ 
2.5 (Fig. 3). 
  
Figure 3. Representative images of the NRG1 FISH assay in GC specimens. a 
NRG1 GCN no gain. b NRG1amplification. c NRG1 GCN gain. 
Evaluation of HER2 status  
HER2 status was determined according to the results of IHC and silver ISH 
(SISH), as described previously [25]. Briefly, HER2 protein expression was 
evaluated according to the DAKO guideline for scoring HercepTestTM in GC. 
HER2 gene status was evaluated using a Ventana BenchMark XT device 
(Ventana Medical Systems). INFORM HER2 DNA and INFORM 
Chromosome 17 (CEP17) were used for automatic SISH staining. HER2 
positivity was indicated when cancer cells had IHC scores of 2+ or 3+ in 
addition to HER2 gene amplification based on SISH. 
 
Microsatellite instability status  
Tissue sections were obtained from formalin-fixed paraffin embedded blocks, 
and both tumor and normal areas were microdissected. After deparaffinization 
with incubation at 70  for 10 min, DNA was extracted using a chelating ion-
exchange resin (Instagene matrix; Bio-Rad, Hercules, CA, USA) according to 
the manufacturer’s instructions. MSI analysis was performed using an ABI 
3731 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA) 
with five microsatellite markers (BAT-26, BAT-25, D5S346, D17S250, and 
D2S123). MSI status was determined into MSI-high (two or more unstable 
markers), MSI-low (one unstable marker), or microsatellite stable (MSS, no 
unstable marker) [25]. 
 
Epstein-Barr virus in situ hybridization 
EBV ISH using a fluorescein-conjugated EBER oligonucleotide probe 
(INFORM EBV-encoded RNA probe, Ventana Medical Systems) was 
performed to determine the EBV status of tumor samples. The cases with 
cancer cells positive for nuclear EBER were considered EBV-positive GC. 
 
Statistical analysis 
SPSS 21.0 (IBM Corp., Armonk, NY) was used for statistical analyses. 
Correlations between NRG1 or HER expression results and clinicopathologic 
variables were examined using Pearson’s chi-square and Fisher’s exact tests. 
The significance of associations with patient outcome was analyzed using 
Kaplan-Meier survival curves and compared using log rank tests. Univariate 
and multivariate analyses were performed for significant prognostic factors 
using Cox regression survival analysis. The concordance of NRG1 assessment 
by IHC and FISH was determined using a Spearman’s rank correlation test. 
Values of P < 0.05 were considered statistically significant. 
RESULTS 
Clinicopathological characteristics of patients   
The clinicopathological characteristics of 502 patients enrolled in this study 
are summarized in Table 1. The median age was 62 years (range 25–89 
years); 332 (66.1%) were male and 170 (33.9%) female. At the time of 
surgical treatment, pTNM stages were distributed as follows: 256 (51.0%) 
cases were at stage I, 78 (15.5%) at stage II, 144 (28.7%) at stage III, and 24 
(4.8%) at stage IV. By the Lauren classification, intestinal, diffuse, and mixed 
type tumors accounted for 217 (43.2%), 240 (47.8%), and 45 (9.0%) cases, 
respectively. Of the 502 cases, 239 (47.6%) had lymph node metastasis. MSI 
status was evaluated in 489 cases, and 40 (8.2%) cases were in the MSI-high 
group. EBV results were available from 501 GCs, among which EBV 
positivity was observed in 50 (10.0%) cases. NRG1 overexpression was 
detected in 141 (28.1%) cases. HER3 cytoplasmic overexpression was present 
in 157 (31.3%) cases, including 13 (2.6%) with membrane staining. 
Cytoplasmic HER4 expression was observed in 277 (55.2%) cases.
Table 1. Clinicopathological characteristics of patients  
Characteristics n (502) 
Age (years), median (range)  62 (25-89) 
Sex, male/female 332/170 
Tumor size (cm) ≤3/>3  158/344 
Tumor location  
Upper third 80 
Middle third 156 
Lower third 252 
Entire 14 
Lauren’s classification  
Intestinal 217 
Diffuse 240 
  Mixed 45 
Ming classification, expanding/infiltrative 185/317 
Vascular invasion, absent/present 445/57 
Lymphatic invasion, absent/present 256/246 
Neural invasion. absent/present 330/172 
Depth of invasion, pT1,2/pT3,4 295/207 
Lymph node metastasis, N0/N+ 263/239 
pTNM stage, I/II/III/IV 256/78/155/24 
Tumor multiplicity, no/yes 471/31 
 
 
Clinicopathologic significance of NRG1, HER3, and 
HER4 expression  
The results of analyses of correlations between clinicopathologic variables are 
presented in Table 2, along with the expression status of NRG1, HER3, and 
HER4. NRG1 overexpression was more frequently identified in GC with 
unfavorable clinicopathologic features, including larger tumor size (P < 
0.001), infiltrative tumor border (P = 0.002), vascular invasion (P = 0.012), 
lymphatic invasion (P < 0.001), neural invasion (P < 0.001), advanced pT 
stage (P < 0.001), lymph node metastasis (P < 0.001), and advanced pTNM 
stage (P < 0.001). However, there was no significant correlation between 
NRG1 positivity by IHC and age, sex, location, or Lauren classification (P = 
0.338, 0.793, 0.244, and 0.150, respectively). Among 502 cases, HER3 
cytoplasmic overexpression correlated strongly with older age (P < 0.001) and 
an expanding tumor border (P = 0.007). HER3 cytoplasmic overexpression 
was also more frequently detected in intestinal or mixed type GC than in 
diffuse type GC (P < 0.001) and tended to be detected in tumors located in the 
lower third of the stomach (P = 0.021). HER4 cytoplasmic expression did not 
show any significant association with clinicopathologic characteristics except 
age (P = 0.011) and histologic type by the Lauren classification (P = 0.007). 
HER2, MSI, and EBV status exhibited no significant correlations with NRG1, 
HER3, or HER4 expression (all P > 0.05) other than a correlation between 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For survival analysis, 501 patients were followed up for 1–109 months, with a 
median follow-up period of 67 months. The remaining single case was lost to 
follow-up after surgery. At the time of analysis, 118 (23.6%) patients had 
tumor recurrence and 110 (22.0%) suffered disease-related death. Kaplan-
Meier survival analysis revealed that patients with GC overexpressing NRG1 
had significantly worse DFS and DSS compared to the NRG1 negative group 
(both P < 0.001); however, there was no difference in DFS or DSS associated 
with HER3 or HER4 cytoplasmic overexpression (both P > 0.05; Fig.4). After 
exclusion of two patients with ≤1 months of follow up, we also performed 
Kaplan-Meier survival analysis, and similar results were observed (Fig. 5). 
Univariate analysis indicated that NRG1 expression and established 
prognostic pathologic factors, including tumor size, non-intestinal histology, 
tumor border, vascular invasion, lymphatic invasion, neural invasion, and 
pathologic stage, were significantly associated with DFS and DSS. By 
multivariate analysis, NRG1 overexpression was identified as an unfavorable 
prognostic factor for DFS (hazard ratio 1.455; 95% confidence interval 1.009–
2.100; P = 0.045) and DSS (hazard ratio 1.490; 95% confidence interval 
1.019–2.177; P = 0.040). Vascular invasion, lymphatic invasion, and pTNM 
stage were independent prognostic factors for both DFS and DSS. Neural 
invasion was also independently associated with DSS (Table 3).  

Figure 4. Kaplan-Meier survival estimates according to NRG1, HER3 and 
HER4 protein expression, and NRG1 gene copy number status. Disease free 
survival and disease specific survival according to a, b NRG1, c, d HER3 
cytoplasmic, e, f HER4 cytoplasmic expression, and g, h NRG1 GCN status.  

Figure 5. Kaplan-Meier survival estimates according to NRG1, HER3 and 
HER4 protein expression (excluding cases with ≤1 months of follow-up). 
Disease free survival and disease specific survival according to a, b NRG1, c, 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Evaluation of NRG1 GCN by FISH 
The median NRG1/CEP8 ratio was 1.03 (range 0.57–5.72). Among the 
available 388 cases, NRG1 GCN gain was detected in 57 (14.7%), including 2 
(0.5%) cases of amplification. When NRG1 GCN status was compared with 
NRG1 protein expression, NRG1 GCN gain was significantly associated with 
NRG1 protein expression (P < 0.001; kappa = 0.459; Table 4). However, the 
two cases withNRG1amplification were negative for NRG1 by IHC analysis, 
and NRG1 GCN gain was not observed in the majority of NRG1 IHC-positive 
cases (65/113, 57.5%). NRG1 GCN gain was significantly associated with 
diffuse or mixed type by the Lauren classification (P = 0.001), lymphatic 
invasion (P = 0.013), and lymph node metastasis (P = 0.013; Table 5). By 
Kaplan-Meier analysis, patients with NRG1 GCN gain had shorter DFS and 
DSS with borderline statistical significance (P = 0.082 and P = 0.078, 
respectively; Fig.2), but Cox regression analysis indicated that NRG1 GCN 
gain was not an independent prognostic factor (P > 0.05). 
Table 4. Correlation between NRG1 immunohistochemistry and gene copy 
number status. 
 NRG1 IHC 
P κ 
 Negative Positive 
NRG1 GCN  
    
  GCN non-gain 266 (80.4%) 65 (19.6%) <0.001 0.459 
  GCN gain 9 (15.8%) 48 (84.2%)   
Table 5. Clinicopathological implications of NRG1 gene copy number gain 
Characteristics 
NRG1 GCN gain (%) 
Negative Positive P  
Total 331 (85.3) 57 (17.4) 
Age (years) 0.746 
 ≤60 147 (86.0) 24 (14.0) 
 >60 184 (84.8) 33 (15.2) 
Sex 0.417 
 Male 220 (84.3) 41 (15.7) 
 Female 111 (87.4) 16 (12.6) 
Tumor size  0.092 
 ≤3cm 100 (90.2) 11 (9.9) 
 >3cm 231 (83.4) 46 (16.6) 
Location 0.665 
 Upper third 55 (85.9) 9 (14.1) 
 Middle third 101 (87.1) 15 (12.9) 
 Lower third 166 (84.7) 30 (15.3) 
 Entire 9 (75.0) 3 (25.0) 
Lauren classification 0.001 
 Intestinal type 151 (89.3) 18 (10.7) 
 Diffuse type 154 (85.6) 26 (14.4) 
 Mixed type 26 (66.7) 13 (33.3) 
Ming classification 0.768 
 Expanding 117 (86.0) 19 (14.0) 
 Infiltrative 214 (84.9) 38 (15.1) 
Vascular invasion 0.982 
 Absent 290 (85.3) 50 (14.7) 
 Present 41 (85.4) 7 (14.6) 
Lymphatic invasion 0.013 
 Absent 169 (89.9) 19 (10.1) 
 Present 162 (81.0) 38 (19.0) 
Neural invasion 0.305 
 Absent 215 (86.7) 33 (13.3) 
 Present 116 (82.9) 24 (17.1) 
Depth of invasion (pT) 0.263 
 T1-T2 189 (87.1) 28 (12.9) 
 T3-T4 142 (83.0) 29 (17.0) 
Lymph node metastasis 0.013 
 N0 169 (89.9) 19 (10.1) 
 N(+) 162 (81.0) 38 (19.0) 
pTNM stage 0.086 
 I-II 219 (87.6) 31 (12.4) 
 III-IV 112 (81.2) 26 (18.8) 
HER2 status 0.224 
 Negative 310 (84.7) 56 (15.3) 
 Positive 21 (95.5) 1 (4.5) 
MSI status (n = 489) 0.408 
 MSS/MSI-L 304 (85.9) 50 (14.1) 
 MSI-H 23 (79.3) 6 (20.7) 
EBV status (n = 501) 0.099 
 Negative 302 (86.3) 48 (13.7) 
 Positive 29 (76.3) 9 (23.7)  
  
Correlation between HER3 membranous expression and 
clinicopathologic factors 
Positive expression of HER3 was predominantly observed in the cytoplasm, 
and 13 of 502 cases (2.6%) also showed HER3 membranous expression (Fig. 
2). GC cases with HER3 membranous expression correlated with lymphatic 
invasion (P = 0.009), lymph node metastasis (P = 0.032), and mixed type 
according to the Lauren classification (P = 0.002), but did not correlate with 
other clinicopathologic factors including MSI and EBV status (all P > 0.05; 
Table 6). GC patients with HER3 membranous expression had an unfavorable 
outcome for DFS (P = 0.018) and DSS (P = 0.015) by survival analysis (Fig. 
6 and Fig. 7). However, it was not an independent prognostic factor by 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6. Survival curves according to a, b HER3 membranous and c, d HER4 
nuclear expression.  
 
Figure 7. Survival curves according to a, b HER3 membranous and c, d HER4 
nuclear expression (excluding cases with ≤1 months of follow-up).  
 
Clinicopathologic significance of HER4 nuclear 
expression 
We next evaluated the clinical significance of HER4 nuclear expression in GC. 
HER4 nuclear expression was observed in 115 (22.9%) of 502 GC cases (Fig. 
2). HER4 nuclear expression was significantly associated with less aggressive 
clinicopathologic features, such as smaller tumor size, expanding tumor 
border, absence of lymphovascular and neural invasion, and early pathologic 
stage (all P < 0.05). HER4 nuclear expression was also associated with 
intestinal type GC with borderline statistical significance (P = 0.052; Table 6). 
In survival analysis, the HER4 nuclear expression group had superior DFS 
and DSS (both P < 0.001; Fig. 6 and Fig. 7); however, in a multivariate hazard 
model, it no longer exhibited prognostic significance for either DFS or DSS 
(P = 0.803 and P = 0.778, respectively; Table 3).  
Correlation of NRG1 expression status with that of its 
receptors 
To investigate associations between NRG1 and its receptors, we evaluated the 
results of NRG1 IHC in comparison with those for HER3 and HER4. As 
shown in Table 7, there was a close association between NRG1 and HER3 
cytoplasmic expression (P = 0.034) and between NRG1 and HER4 
cytoplasmic expression (P < 0.001). However, HER3 membranous expression 
and HER4 nuclear expression were not correlated with NRG1 expression, 
contrary to its cytoplasmic expression (P = 0.763 and P = 0.084, respectively).
Table 7. Correlation between expression of NRG1, HER3, and HER4 
 NRG1 
   Negative   Positive P 
HER3 (cytoplasm) 0.034 
  Negative 258 (74.8%) 87 (25.2%) 
  Positive 103 (65.6%) 54 (34.4%) 
HER3 (membrane)   0.763 
  Negative 352 (72.0%) 137 (28.0%) 
  Positive 9 (69.2%) 4 (30.8%) 
HER4 (cytoplasm) <0.001 
  Negative 184 (81.8%) 41 (18.2%) 
  Positive 177 (63.9%) 100 (36.1%) 
HER4 (nucleus) 0.084 
  Negative 271 (70.0%) 116 (30.0%) 
  Positive 90 (78.3%) 25 (21.7%)  
 
  
NRG1 and HER3 expression in GC patients receiving 
trastuzumab combined chemotherapy 
Next, we collected 14 HER2 positive GC patients who had chemotherapy 
combined with HER2 inhibitor, trastzumab, and performed 
immunohistochemical analysis of NRG1 and HER3. Based on the results of 
previous studies that NRG1/HER3 signaling was associated with development 
of resistance to HER2-targeted treatment [8-11], we inferred that 
NRG1/HER3 coexpression group showed worse prognosis in trastzumab 
treated GC patients. The results of immunohistochemical staining were 
presented in Table 8 and Fig. 8. Among a total of 14 cases, NRG1 and HER3 
expression were observed in 3 (21.4%) and 5 (35.7%), respectively. The 
coexpression of NRG1 and HER3 was found in 2 (14.3%) cases. Interestingly, 
HER3 expression was detected on membrane and/or cytoplasm of cancer cells. 
We analyzed the survival difference according to expression status of NRG1 
and HER3. Each NRG1 and HER3 positive group showed a tendency of 
shorter progression free survival (PFS), but the statistical significance was not 
reached (P = 0.582 and P = 0.215, respectively; Fig. 9). NRG1 and HER3 
coexpressed GC group also showed a shorter PFS, in agreement with our 
hypothesis (P = 0.005, Fig. 9). More validated studies for prognostic features 
and chemotherapy responses according to the NRG1/HER3 status in larger 
cohort of GC are necessary. 
Table 8. Clinicopathologic characteristics of HER2 positive and trastzumab 
treated GC cases and immunohistochemical staining of NRG1 and HER3  
 
 
Figure 8. NRG1 and HER3 expression in HER2 positive GC patients who 
had chemotherapy combined with HER2 inhibitor, trastzumab. a NRG1. b 
HER3.
 
Figure 9. Kaplan-Meier survival analysis accoridng to NRG1 and HER3 
expression in HER2 positive and trastzumab treated GC patients. Progression 











To date, the clinicopathologic role of NRG1 in GC has been unclear; therefore, 
we investigated the clinicopathologic implications and prognostic value of 
NRG1 expression in GC specimens. NRG1 overexpression was observed in 
28.1% of GC samples, and NRG1 status was strongly associated with 
aggressive clinicopathologic parameters, including larger tumor size, 
infiltrative tumor border, lymphovascular invasion, neural invasion, lymph 
node metastasis, and advanced pathologic stage. Additionally, the 
overexpression of NRG1 predicted poor prognosis in patients with GC. To the 
best of our knowledge, this is the first study to demonstrate the 
clinicopathologic significance of NRG1 expression in a large-scale study of 
GC.  
 
NRG1, a member of the NRG family, acts by binding to HER3 and HER4. 
HER3 is considered the major receptor for NRG1 [26, 27]. Recently, NRG1 
has become the focus of research attention because of its overexpression in 
various cancers, including breast, urinary bladder, colorectal, prostate, and 
lung cancers [6]. In breast cancer, NRG1 overexpression was observed in 
approximately 30–80% of cases. In addition, NRG1 overexpression has been 
implicated in the activation of the HER3/HER2 signaling pathway, which 
mediates cancer cell proliferation, and other malignant features, including 
tumor invasion and metastasis [28–30]. Despite the increasing focus on NRG1 
in various cancers, few studies have investigated the expression of NRG1 and 
its association with clinical outcome in GC. Han et al. [23] reported that 
NRG1 overexpression was significantly related to advanced pathologic stage, 
lymph node metastasis, and poor prognosis; however, there have been several 
conflicting reports on the prognostic significance of NRG overexpression in 
various cancers [31–33]. Our results indicate that NRG1 overexpression is 
strongly associated with unfavorable clinicopathologic features in GC. 
Moreover, we identified pronounced differences between outcomes in GC 
patients with or without NRG1 overexpression. Hence, the results of the 
present study suggest that NRG1 overexpression may be an independent poor 
prognostic factor in GC. 
 
Because of the close relationship between NRG1 and HER3, NRG1 
expression has been suggested as a predictive biomarker for HER3 inhibition 
[6, 11]. In addition, NRG1 can promote resistance to HER2-targeted therapy 
through activation of HER3 and PI3K/Akt signaling both in vivo and in vitro 
[9, 34, 35]. Furthermore, a combination of anti-HER2 treatment with 
administration of a HER3 inhibitor has been proposed as a promising 
therapeutic strategy to improve tumor regression [36]. Therefore, our NRG1 
expression and GCN results provide basic information of potential use for the 
development of clinical trials of HER3 inhibitor therapy and combined HER2 
and HER3 inhibitor therapy. The expression and genetic status of NRG1 may 
facilitate identification of a GC patient subgroup who could benefit from anti-
HER3 treatment. 
 
Previous studies demonstrated that HER3 was overexpressed in the cytoplasm 
or membrane of tumor cells, which predicted poor prognosis in GC [15, 37, 
38]. However, in our result, patients with cytoplasmic expression of HER3 
have suffered slightly shorter DFS and DSS, without statistical significance (P 
> 0.05), and HER3 cytoplasmic expression did not correlate with lymph node 
metastasis or stage (P > 0.05). The survival analyses of HER3 expression may 
be affected by histologic subtypes and intracellular sublocalization 
(cytoplasmic vs. membranous). It may be additionally influenced by the 
sample size, race, ethnicity, antibody sources, and immunostaining protocol. 
Our results showed that HER3 cytoplasmic expression was significantly 
associated with HER2 positivity (P = 0.022) and the intestinal type of the 
Lauren classification (P < 0.001), and by subgroup analysis, HER3 
cytoplasmic expression was associated with unfavorable prognosis in diffuse 
type GC (P = 0.025), but not in intestinal type (P > 0.05, data not shown), 
consistent with most previous studies [39, 40].  
Interestingly, we found that GCs with membranous expression of HER3 
showed significantly worse outcomes. In HER2 positive and trastzumab 
treated GC cohort, HER3 expression was found mainly on membrane, with or 
without cytoplasm of cancer cell, and all these five cases with HER3 
expression suffered tumor progression. In Kaplan-Meier survival curve, 
HER3 expression group tended to show shorter PFS than in HER3 negative 
group. Based on these results, we suggest that HER3 membranous expression, 
not cytoplasmic localization, may have a significant role in HER2 positive 
and trastzumab treated GC patients. 
  
Recent studies have also highlighted the clinical implications of HER4, since 
its expression is detected in various cancers [18, 41, 42]. Notably, HER4 has 
two conflicting roles in cancer. It can both inhibit and promote cell 
proliferation, depending on the localization of different HER4 isoforms 
generated by alternative splicing [18–20]. Alternative splicing of the HER4 
gene leads to the production of two intracytoplasmic isoforms, CYT1 and 
CYT2. Compared with CYT2, translocation into the nucleus by CYT1 is less 
efficient. CYT1 also can induce the PI3K/Akt pathway, leading to increased 
cell proliferation and inhibition of cell differentiation [19, 43]. Depending on 
the presence of these isoforms, HER4 may show different intracellular 
localizations and varying clinical significance in malignancies. Previous 
studies on HER4 expression in GC failed to demonstrate a significant 
association with patients survival [15, 39], and little is known about the 
function of NRG1 in relation to the subcellular distribution of HER4 in GC. In 
a review of breast cancer studies, while HER4 cytoplasmic expression was 
favorably associated with patient survival, the significance of HER4 
expression localized to the nucleus with regard to survival was uncertain [18]. 
In the current analysis, we evaluated HER4 nuclear and cytoplasmic 
expression independently in GC, according to the localization of 
immunostaining. We found that HER4 nuclear expression was tightly 
associated with favorable clinicopathologic features and better survival rates 
in GC; however, HER4 cytoplasmic expression failed to show a significant 
association with these parameters, in contrast to the reported results for this 
protein in breast cancer. Moreover, NRG1 expression was tightly related to 
cytoplasmic expression of HER4 and exhibited an inverse association with 
HER4 nuclear expression, with borderline statistical significance. Considering 
the conflicting role of HER4 in cancer, our findings suggested that HER4 
nuclear rather than cytoplasmic expression might be related to favorable 
clinical characteristics. 
 
Our results demonstrate that NRG1 amplification is a relatively rare event 
(0.5%) in GC. This is consistent with the findings of a previous study, which 
demonstrated that NRG1 amplification is infrequent in GC [23]; however, 
alterations in NRG1 GCN have not previously been investigated in GC. 
Despite the lack of acknowledged consensus criteria for GCN gain, our results 
revealed that this phenomenon was observed with relatively low frequency 
(14.7%). Additionally, we compared NRG1 protein expression and gene status. 
A significant discrepancy between NRG1 GCN alteration and protein 
expression was identified, with cancer cells exhibiting NRG1 amplification 
found to be negative for NRG1 immunostaining. One possible explanation for 
this discrepancy is that NRG1 may be overexpressed through mechanisms 
other than GCN alteration or gene amplification. 
 
Our study has some limitations, including sampling bias of TMA slides, the 
use of a single institute retrospective cohort, and a lack of inclusion of patients 
receiving HER3 inhibitor therapy. Therefore, further comprehensive studies 
and clinical trials are necessary to clarify the usefulness of NRG1 for the 
identification of cases where anti-HER3 treatment would be appropriate. 
 
In conclusion, we evaluated the clinical significance of NRG1 and its 
receptors, including HER3 and HER4, in a large cohort of patients with GC. 
NRG1 was frequently overexpressed, and its expression was highly correlated 
with the cytoplasmic expression of HER3 and HER4 in GC. We also 
identified a strong correlation between high levels of NRG1 protein 
expression and increased NRG1 GCN. Moreover, overexpression of this 
protein was significantly associated with aggressive behavior of GC including 
poor prognosis. However, prognostic significance of the expression of HER3, 
HER4 according to the intracellular sublocalization, was uncertain. These 
results suggest that NRG1 overexpression may predict poor clinical outcome 
and that targeting NRG1 represents a therapeutic opportunity in GC. 
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